Dyne Therapeutics, Inc.
DYN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.48 | -0.15 | -0.36 | -0.03 |
| FCF Yield | -13.29% | -23.80% | -26.01% | -20.36% |
| EV / EBITDA | -5.73 | -3.00 | -2.80 | -2.95 |
| Quality | ||||
| ROIC | -52.21% | -204.00% | -56.58% | -37.07% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.92 | 0.80 | 0.91 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -56.04% | -20.53% | -27.22% | -158.41% |
| Safety | ||||
| Net Debt / EBITDA | 1.31 | 0.40 | 0.86 | 1.13 |
| Interest Coverage | 0.00 | 0.00 | -58.61 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,067.82 | -3,401.72 | -573.85 | -1,352.31 |